Clinical Features and Therapeutic Evaluation of Central Nervous System Involvement in Pediatric Anaplastic Large Cell Lymphoma

• Published in: Blood 2023-11, Vol.142 (Supplement 1), p.1709-1709
• Main Authors: Yang, Xiaomei, Yang, Jing, Huang, Shuang, Duan, Yanlong, Jin, Ling, Li, Fu, Du, Lian, Zheng, Mincui, Wu, Pan, Liu, Ying, Hu, Bo, Dai, Yunpeng, Guan, Guotao, Liu, Ansheng, Qin, Shuang, Sun, Lirong, Jiang, Jian, Liu, Wei, Zhou, Jianwen, Wang, Jian, Qu, Lijun, Zhang, Leping, Jia, Yueping, Yuan, Xiaojun, Dong, Yushuang, Zhang, Baoxi, Jiang, Lian, Wang, ZhuJun, Wang, XiGe, Zhuang, Shuquan, Zhou, Chunju, Gao, Zifen, Zhang, Yonghong
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2023-188173

Objective：To analyze the clinical features of central nervous system involvement (CNS3) in pediatric anaplastic large cell lymphoma (ALCL) and evaluate the efficacy of CNCL-ALCL-2017 protocol for the treatment of CNS3. Methods：The clinical data of 215 pediatric ALCL patients ≤18 years old enrolled in the Chinese Children's Cancer Group (CNCL) between April 2017 and March 2023 were collected sequentially. All enrolled patients staging and CNS layering were according to the IPNHLSS staging system and treated with CNCL-ALCL-2017 protocol (modified BFM-ALCL99 protocol). The clinical features at diagnosis and treatment outcomes of CNS3 patients were analyzed. All patients were followed up until June 30, 2023. Data were collected using a unified information platform. Associations between patient characteristics were analyzed with Chi-squared or Fisher's exact tests. Eventfree survival (EFS) and overall survival (OS) curves were estimated according to the KaplanMeier method and compared by Logrank test. Furthermore, statistical analysis was performed using SPSS 22.0 software. P